Omega-3 Fatty Acids Provide No Beneficial Effects to Patients With Multiple Sclerosis
CHICAGO -- April 17, 2012 -- Omega-3 fatty acid supplements were not associated with beneficial effects on disease activity in patients with relapsing-remitting multiple sclerosis (MS) according to a study published online first in the Archives of Neurology.
Some patients with MS use omega-3 fatty acids supplementation to control the disease because the essential fatty acids could theoretically have anti-inflammatory and neuroprotective effects.
Øivind Torkildsen, MD, Haukeland University Hospital, Bergen, Norway, and colleagues examined whether omega-3 fatty acid supplementation as a monotherapy (single therapy) or in combination with subcutaneous interferon beta-1a could reduce disease activity.
The researchers randomised 92 patients to receive either eicosapentaenoic acid
1350 mg and docosahexaenoic acid 850 mg daily (n = 46) or a placebo (n = 46).
After 6 months, all patients received interferon beta-1a 3qW for another 18 months. Researchers used magnetic resonance imaging (MRI) to measure disease activity by the number of new T1-weighted gadolinium-enhancing lesions in the brain.
“The results from this study did not show any beneficial effects of omega-3 fatty acid supplementation on disease activity in MS as a monotherapy or in combination with interferon beta,” the authors wrote.
They noted that their results were in contrast with 2 other studies reporting a possible positive effect.
The median number of new T1-weighted gadolinium-enhancing lesions was 3 in the
omega-3 fatty acid group and 2 in the placebo group during the first 6 months.
The results indicate no difference between the 2 groups in the number of relapses during the first 6 months of treatment or after 24 months. No differences were detected either in fatigue or quality-of-life scores.
However, the authors commented that their data do not suggest that omega-3 fatty acid supplementation was harmful or that it interfered with interferon beta treatment, which they noted can reduce disease activity in the relapsing-remitting course of the disease.
“The design of this study allowed us to compare the effect of omega-3 fatty acid supplementation both against placebo alone and in combination with interferon beta,” they concluded. “As expected, the MRI disease activity was significantly reduced when interferon beta-1a was introduced.”
SOURCE: Archives of Neurology
CHICAGO -- April 17, 2012 -- Omega-3 fatty acid supplements were not associated with beneficial effects on disease activity in patients with relapsing-remitting multiple sclerosis (MS) according to a study published online first in the Archives of Neurology.
Some patients with MS use omega-3 fatty acids supplementation to control the disease because the essential fatty acids could theoretically have anti-inflammatory and neuroprotective effects.
Øivind Torkildsen, MD, Haukeland University Hospital, Bergen, Norway, and colleagues examined whether omega-3 fatty acid supplementation as a monotherapy (single therapy) or in combination with subcutaneous interferon beta-1a could reduce disease activity.
The researchers randomised 92 patients to receive either eicosapentaenoic acid
1350 mg and docosahexaenoic acid 850 mg daily (n = 46) or a placebo (n = 46).
After 6 months, all patients received interferon beta-1a 3qW for another 18 months. Researchers used magnetic resonance imaging (MRI) to measure disease activity by the number of new T1-weighted gadolinium-enhancing lesions in the brain.
“The results from this study did not show any beneficial effects of omega-3 fatty acid supplementation on disease activity in MS as a monotherapy or in combination with interferon beta,” the authors wrote.
They noted that their results were in contrast with 2 other studies reporting a possible positive effect.
The median number of new T1-weighted gadolinium-enhancing lesions was 3 in the
omega-3 fatty acid group and 2 in the placebo group during the first 6 months.
The results indicate no difference between the 2 groups in the number of relapses during the first 6 months of treatment or after 24 months. No differences were detected either in fatigue or quality-of-life scores.
However, the authors commented that their data do not suggest that omega-3 fatty acid supplementation was harmful or that it interfered with interferon beta treatment, which they noted can reduce disease activity in the relapsing-remitting course of the disease.
“The design of this study allowed us to compare the effect of omega-3 fatty acid supplementation both against placebo alone and in combination with interferon beta,” they concluded. “As expected, the MRI disease activity was significantly reduced when interferon beta-1a was introduced.”
SOURCE: Archives of Neurology
Comment